LUYE PHARMA(02186),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02186 LUYE PHARMA

Closed 12-22 16:08:10

2.860

-0.020

-0.69%

High2.900	Low2.840	Vol11.66M
Open2.880	D1 Closing2.880	Amplitude2.08%
Mkt Cap11.43B	Tradable Cap11.43B	Total Shares4.00B
T/O33.37M	T/O Rate0.29%	Tradable Shares4.00B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02186","market":"HK","secType":"STK","nameCN":"LUYE PHARMA","latestPrice":2.86,"timestamp":1766390890005,"preClose":2.88,"halted":0,"volume":11661000,"delay":0,"floatShares":3995000000,"shares":3995000000,"eps":0.13877223214494086,"marketStatus":"Closed","change":-0.02,"latestTime":"12-22 16:08:10","open":2.88,"high":2.9,"low":2.84,"amount":33367241,"amplitude":0.020833,"askPrice":2.86,"askSize":132000,"bidPrice":2.85,"bidSize":203500,"shortable":3,"etf":0,"ttmEps":0.11670828244482649,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766453400000},"marketStatusCode":5,"adr":0,"listingDate":1404835200000,"exchange":"SEHK","adjPreClose":2.88,"openAndCloseTimeList":[[1766367000000,1766376000000],[1766379600000,1766390400000]],"volumeRatio":0.950681,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02186","defaultTab":"news","newsList":[{"id":"2591169209","title":"Luye Pharma Unit Completes Sale of Boan Biotech-Linked Exchangeable Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2591169209","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591169209?lang=en_us&edition=fundamental","pubTime":"2025-12-15 13:06","pubTimestamp":1765775210,"startTime":"0","endTime":"0","summary":"Luye Pharma Group (HKG:2186) said a wholly owned unit completed the issue of $150 million in exchangeable preference shares to an independent subscriber, according to a Hong Kong bourse filing Friday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06955","BK1161","BK1191","BK1583","02186","BK1606"],"gpt_icon":0},{"id":"1117725675","title":"LUYE PHARMA Subsidiary Completes Issuance of 1.5 Million Exchangeable Preferred Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1117725675","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117725675?lang=en_us&edition=fundamental","pubTime":"2025-12-15 08:40","pubTimestamp":1765759223,"startTime":"0","endTime":"0","summary":"LUYE PHARMA (02186) announced that on December 12, 2025, the issuance of exchangeable preferred shares was completed in accordance with the terms of the subscription agreement. The issuer, Luye...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1606","02186","BK1191"],"gpt_icon":0},{"id":"2591890652","title":"Luye Pharma Group (SEHK:2186): Valuation Check After New Exchangeable Preference Share Deal in Boan Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=2591890652","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591890652?lang=en_us&edition=fundamental","pubTime":"2025-12-14 06:14","pubTimestamp":1765664071,"startTime":"0","endTime":"0","summary":"Luye Pharma Group (SEHK:2186) just wrapped up a financing move through its subsidiary, issuing 1,500,000 exchangeable preference shares tied to Boan Biotech’s stock, effectively tightening its grip on the biotech side of the business.\nSee our latest analysis for Luye Pharma Group.\nThe latest exchangeable preference share issuance comes after a year in which Luye Pharma’s 38.68% year to date share price return contrasts with a still negative 5 year total shareholder return of 21.81%. This...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2186/luye-pharma-group-shares/news/luye-pharma-group-sehk2186-valuation-check-after-new-exchang","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2186/luye-pharma-group-shares/news/luye-pharma-group-sehk2186-valuation-check-after-new-exchang","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02186","BK1191","DCF","BK1606","BK1583"],"gpt_icon":0},{"id":"1176073330","title":"LUYE PHARMA (02186) Subsidiary Completes Issuance of 1.5 Million Exchangeable Preferred Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1176073330","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176073330?lang=en_us&edition=fundamental","pubTime":"2025-12-12 22:48","pubTimestamp":1765550895,"startTime":"0","endTime":"0","summary":"LUYE PHARMA (02186) announced that on December 12, 2025, the issuance of exchangeable preferred shares was completed in accordance with the terms of the subscription agreement. The issuer, Luye...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02186","BK1606","BK1583"],"gpt_icon":0},{"id":"2590502652","title":"Luye Pharma Subsidiary Issues Exchangeable Preference Shares to Bluebell Asset Holding","url":"https://stock-news.laohu8.com/highlight/detail?id=2590502652","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590502652?lang=en_us&edition=fundamental","pubTime":"2025-12-12 22:30","pubTimestamp":1765549857,"startTime":"0","endTime":"0","summary":"Luye Pharma Group Ltd. announced the completion of a discloseable transaction involving the issue of 1,500,000 exchangeable preference shares by its wholly-owned subsidiary, Luye Geneora Holding Limited. The shares were subscribed by Bluebell Asset Holding Ltd., an investment holding company focused on the healthcare sector in Asia and ultimately owned by RRJ Capital. The proceeds from this transaction will be used for the group's general working capital purposes, including payments to suppliers, employee salaries, directors' remuneration, and other management and administrative expenses.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Luye Pharma Group Ltd. published the original content used to generate this news brief via IIS, the Is","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL6w2Y1N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","02186","BK1191","BK1583"],"gpt_icon":0},{"id":"2590452112","title":"Private companies are Luye Pharma Group Ltd.'s (HKG:2186) biggest owners and were hit after market cap dropped HK$639m","url":"https://stock-news.laohu8.com/highlight/detail?id=2590452112","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590452112?lang=en_us&edition=fundamental","pubTime":"2025-12-12 06:34","pubTimestamp":1765492480,"startTime":"0","endTime":"0","summary":"Key Insights The considerable ownership by private companies in Luye Pharma Group indicates that they collectively have...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2186/luye-pharma-group-shares/news/private-companies-are-luye-pharma-group-ltds-hkg2186-biggest-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2186/luye-pharma-group-shares/news/private-companies-are-luye-pharma-group-ltds-hkg2186-biggest-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1606","BK1191","02186","BK1583"],"gpt_icon":0},{"id":"2589388084","title":"Luye Pharma Says Five New Products Added to China's Drug Reimbursement List","url":"https://stock-news.laohu8.com/highlight/detail?id=2589388084","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589388084?lang=en_us&edition=fundamental","pubTime":"2025-12-08 11:08","pubTimestamp":1765163295,"startTime":"0","endTime":"0","summary":"Luye Pharma Group  said five new products were added to China's latest list of drugs eligible for reimbursement, according to a Hong Kong bourse filing Sunday.Shares of the company gained over 1% in morning trade Monday.Of the five products, opioid painkiller Mimeixin and schizophrenia treatment Ruibailai were added to China's National Reimbursement Drug List for the first time, while lung cancer treatment Zepzelca was included in the Commercial Insurance Innovative Drug List.Meanwhile, cancer drug Baituowei and chronic schizophrenia treatment Rykindo's inclusion was renewed, the firm said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1606","BK1191","02186","BK1583"],"gpt_icon":0},{"id":"1145915321","title":"HK Stock Movement | LUYE PHARMA (02186) Rises Nearly 3% as Five New Products Including Mimexin® Included in National Reimbursement Drug List or Commercial Insurance Innovative Drug Directory","url":"https://stock-news.laohu8.com/highlight/detail?id=1145915321","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145915321?lang=en_us&edition=fundamental","pubTime":"2025-12-08 09:57","pubTimestamp":1765159030,"startTime":"0","endTime":"0","summary":"LUYE PHARMA (02186) rose nearly 3%, with a gain of 2.66% at the time of writing, trading at HK$3.09 and a turnover of HK$8.3751 million. On December 7, LUYE PHARMA announced that five of its new...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186","BK1583","BK1574","BK1191","BK1606","BK1161","06978","159992"],"gpt_icon":0},{"id":"1151283630","title":"LUYE PHARMA (02186) Successfully Includes Five New Products in 2025 National Reimbursement Drug List or Commercial Insurance Innovative Drug Directory","url":"https://stock-news.laohu8.com/highlight/detail?id=1151283630","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151283630?lang=en_us&edition=fundamental","pubTime":"2025-12-07 18:46","pubTimestamp":1765104372,"startTime":"0","endTime":"0","summary":"LUYE PHARMA (02186) announced that five of its new products have been successfully included in either the \"National Reimbursement Drug List (2025)\" or the \"Commercial Health Insurance Innovative Drug...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","159992","02186","BK1583","BK1574","BK1191","BK1606","BK1161"],"gpt_icon":0},{"id":"1193738096","title":"Southbound Capital Flow Data (T+2) for Hong Kong Stocks | November 27","url":"https://stock-news.laohu8.com/highlight/detail?id=1193738096","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193738096?lang=en_us&edition=fundamental","pubTime":"2025-11-27 07:34","pubTimestamp":1764200086,"startTime":"0","endTime":"0","summary":"On November 24, Alibaba-W (09988), Tencent (00700), and Kuaishou-W (01024) topped the market in terms of net southbound capital inflows, recording inflows of HK$4.06 billion, HK$1.168 billion, and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0469268626.HKD","BK1171","LU0516423174.USD","LU1366334578.USD","BK1521","LU2488822045.USD","LU1023057109.AUD","LU0228367735.SGD","03968","LU1211504680.USD","LU0630378429.USD","LU1044876610.USD","LU2237443549.SGD","03918","LU0289960550.SGD","IE00B97KM107.HKD","LU0541502299.USD","SGXZ31699556.SGD","LU0149721374.USD","IE0031814852.USD","SG9999017495.SGD","HK0000320223.HKD","LU2152927971.USD","LU2097828714.EUR","01801","LU1105468828.SGD","LU2251237488.HKD","BK1129","SG9999000418.SGD","LU0762541174.USD","LU1804176565.USD","BK1140","03306","LU0169518387.USD","SG9999003461.SGD","LU1770034418.SGD","BK1517","BK1528","LU0541501648.USD","BK1175","LU0856984785.SGD","BK1513","IE0008369823.USD","LU0700851271.USD","LU1675838814.USD","SG9999013353.USD","BK1202","LU0417516902.SGD","LU0868486357.SGD","IE00BZ08YS42.EUR","LU0307460666.USD","LU0572940350.SGD","LU2237443622.USD","LU0577902538.SGD","HKXCY","LU0823040885.USD","LU1152091754.HKD","LU0188438112.USD","LU0823397285.USD","LU0873338254.USD","IE00B031HW06.USD","LU0882747503.HKD","LU0359201612.USD","LU0192582467.USD","LU2265009873.SGD","LU0651947912.USD","LU0786609619.USD","LU0918141887.USD","IE0008368411.USD","SG9999001846.SGD","LU0488056044.USD","LU3063872942.SGD","LU1568876251.USD","LU1868838027.USD","SG9999015978.USD","LU0823039010.USD","LU1196710195.USD","LU0080751232.USD","LU0605514214.HKD","HMTD.SI","LU0164865239.USD","BK1095","LU1201861165.SGD","BK1501","LU2237443465.HKD","LU0175139822.USD","BK1183","BK1125","LU0878005551.USD","BK1147","00941","LU0370786039.SGD","BK1560","LU0203345920.USD","LU1522347837.USD","02600","LU0463099449.HKD","SG9999002828.SGD","LU0791590937.USD","LU0821914370.USD","LU0128522744.USD","IE00BQXX3C00.GBP","LU0244354667.USD","LU1807302812.USD","LU1497734951.SGD","LU1733274390.USD","LU0348783662.USD","BK1238","LU0831093199.SGD","LU2293587155.HKD","02460","LU0048597586.USD","LU0345775950.USD","00388","HEXmain","LU0588546209.SGD","LU0293314216.USD","LU0384037296.USD","89988","LU0455707207.USD","LU0348825331.USD","BK1564","LU1196710351.USD","BK1193","BK1516","IE0003795394.USD","LU1115378108.SGD","IE0009570106.USD","LU0210527791.USD","LU0672654166.SGD","LU0345780521.USD","LU0543330566.HKD","LU1226288170.HKD","LU1282649067.USD","LU0039217434.USD","SG9999014880.SGD","LU0210533765.USD","SG9999002562.SGD","LU0329678337.USD","LU0266512127.USD","BK1104","LU0231483743.USD","LU2476274308.USD","SG9999001093.SGD","LU0456854461.SGD","LU1226287529.USD","LU1961090484.USD","IE00BKZH1Z71.USD","LU1515016050.SGD","BK1567","LU0886674414.USD","01810","LU1720051108.HKD","LU0572939691.SGD","81810","LU1880383366.USD","LU0871576103.HKD","BK1235","BK1539","LU2449936058.SGD","BK1184","IE00B0169L03.USD","BK1523","BK1249","BK1530","BK1505","03143","LU0348767384.USD","LU0572944931.SGD","LU0456842615.SGD","LU1102505762.USD","LU0880133367.SGD","LU1282651048.USD","LU1720051017.SGD","HK0000165453.HKD","SG9999018857.SGD","LU1303224171.USD","BK1190","LU0499858438.USD","LU0287142896.SGD","LU0456827905.SGD","MIUmain","LU0326950275.SGD","LU0348783233.USD","LU0431992006.USD","SGXZ99366536.SGD","BK1606","01336","LU0165289439.USD","HK0000320264.USD","SG9999014906.USD","BK1237","LU0417516738.SGD","LU2237443978.SGD","BK1526","LU0589944569.HKD","LU2045819591.USD","SG9999000459.SGD","BK1531","IE0032834883.USD","BK1509","LU0985320562.USD","LU1242518931.SGD","LU1008478684.HKD","LU1044875133.USD","01921","LU0143863198.USD","LU0048580855.USD","LU1880383440.USD","LU0164880469.USD","00883","LU2242644610.SGD","02016","LU0214875030.USD","LU0898667661.SGD","BK1568","SG9999001051.SGD","LU0441854154.USD","81024","LU0143863784.USD","LU0651946864.USD","LU1733274473.HKD","LU0130103400.USD","LU1226288097.SGD","LU1568876335.HKD","IE00B0JY6N72.USD","LU0117844026.USD","LU0588545730.USD","LU0650527681.SGD","LU1548497426.USD","09690","LU0048388663.USD","LU1251922891.USD","BK1584","LU0261950983.USD","LU0449509016.USD","XIACY","IE00B031J352.USD","LU1718418525.SGD","LU1366334651.USD","LU1316542783.SGD","LU1642822792.SGD","BK1172","LU2362540622.SGD","00700","LU1048588211.SGD","LU1769817179.HKD","LU1188198961.HKD","LU0634319403.HKD","LU0061477393.USD","LU1282649810.SGD","LU0054450605.USD","BK1124","LU1439103000.SGD","LU0149534421.HKD","LU0264606111.USD","LU0106959298.USD","LU0107464264.USD","LU0130518102.USD","LU1725190679.HKD","LU0181495838.USD","BK1589","BK1163","LU0708995153.HKD","LU0611395673.USD","LU0890818403.SGD","BK1227","LU0762540952.USD","BK1158","LU0823426480.USD","LU0235996351.USD","LU0348816934.USD","LU1634259391.SGD","LU0642271901.SGD","LU0499858602.USD","LU0828237510.HKD","BK1609","LU0128522157.USD","LU2362541273.HKD","LU0067412154.USD","LU0828238088.HKD","LU1235295612.USD","LU0737861699.HKD","LU1974910355.USD","LU1880398471.USD","SG9999004220.SGD","LU0502904849.HKD","LU2106854487.HKD","LU1785774172.SGD","LU2462611646.USD","BK1185","LU0819123356.HKD","LU2097828474.EUR","LU0320764599.SGD","LU0254981946.USD","IE0008368304.USD","IE00BVYPNQ40.USD","LU0259732245.USD","LU0359202008.SGD","LU0417516571.SGD","LU2125910849.SGD","BK1142","01052","00981","BK1615","LU2148510915.USD","LU2087589342.USD","BK1209","IE00BVYPNP33.GBP","LU1868837722.USD","SG9999015952.SGD","LU1046422090.SGD","LU2251237306.USD","03690","SG9999014898.SGD","LU0588545490.SGD","LU0791591158.USD","IE00BZ08YR35.GBP","LU0797268264.HKD","01375","HK0000500386.USD","LU0261947096.USD","06963","LU0516422952.EUR","LU0737861772.HKD","LU0345769631.USD","LU0203347892.USD","IE00BMCWC346.EUR","LU1048596156.SGD","SG9999015986.USD","BK1575","LU1769817096.USD","00489","IE0003895053.USD","LU1720050803.USD","LU0594300419.USD","LU0314109678.HKD","LU1130305938.SGD","LU0648948544.HKD","SG9999001069.SGD","LU1883866441.USD","LU0683595622.HKD","IE00B067MR52.USD","IE00BPRC5H50.USD","BK1198","LU0348788117.USD","LU1956131251.USD","01024","LU0345769128.USD","LU0823038988.USD","LU0456846285.SGD","LU0593848301.USD","LU0955648018.USD","IE00B3M56506.USD","LU1497733631.SGD","LU2357305700.SGD","LU0345780281.USD","02899","LU0594300179.USD","LU1282649141.HKD","LU0675040207.SGD","LU0210526637.USD","BK1607","LU0320764755.SGD","LU0315179316.USD","LU0762542818.HKD","IE0032431581.USD","LU0831103253.SGD","LU0070217475.USD","BK1536","LU2778985437.USD","METmain","LU0348805143.USD","BK1591","IE00BF5LJ272.USD","LU1917777945.USD","LU0640798160.USD","LU1634259557.SGD","LU1813983027.USD","BK1200","LU1688375341.USD","LU0327786744.USD","09626","LU0197773673.USD","09660","LU2023250504.SGD","BK1583","IE00B5MMRT66.SGD","SG9999002463.SGD","IE0034224299.USD","LU0196878994.USD","LU0708995583.HKD","LU1719994722.HKD","LU2226246903.HKD","02609","SGXZ51526630.SGD","LU0819121731.USD","SG9999007991.SGD","03441","LU0266512473.USD","LU1629966141.USD","IE0008368742.USD","LU0823426308.USD","IE00BMPRXR70.SGD","LU2399975544.HKD","LU2257852520.SGD","LU2237443895.HKD","LU0608807946.USD","IE0003851619.USD","LU0029875118.USD","LU0955669360.SGD","BK1161","LU0106259558.USD","LU0072462343.USD","LU0561508036.HKD","LU1880398554.USD","LU0516423091.SGD","LU2097828557.USD","LU1282651121.HKD","LU0588545904.SGD","LU0630378692.HKD","IE00B543WZ88.USD","LU2051468812.USD","LU1064131003.USD","LU0540923850.HKD","HK0000306701.USD","02186","HK0000252152.HKD","LU0051755006.USD","LU0823041008.USD","LU0828237940.HKD","LU1328615791.USD","LU0972618739.USD","HK0000306685.HKD","LU0329678170.USD","LU0029874905.USD","03618","LU1328277881.USD","IE00BGHQDM52.EUR","LU1044874839.SGD","IE00BMPRXN33.USD","LU1868837565.USD","LU2008162690.USD","IE00BQXX3D17.EUR","BK1588","LU0648000940.SGD","LU1504937902.USD","LU0862451837.USD","LU0577902611.USD","SG9999015945.SGD","LU2125910500.SGD","IE00B8L5B284.USD","LU2328871848.SGD","BK1618","BK1537","LU0211977185.USD","LU0577902371.SGD","LU0251144936.SGD","LU0315178854.USD","LU2476274720.SGD","IE00BZ08YT58.USD","HK0000252160.HKD","LU0127658192.USD","BK1594","LU0047713382.USD","00990","HBBD.SI","LU2362541513.USD","BK1119","LU2039709279.SGD","LU0054237671.USD","IE00BQXX3F31.USD","LU0359201885.HKD","BK1590","LU0106252389.USD","LU1242518857.USD","LU1993786604.SGD","LU0132412106.USD","BK1109","BK1231","LU0228659784.USD","SG9999001903.USD","LU0531971595.HKD","HXXD.SI","01772","SG9999018865.SGD","02172","LU0348735423.USD","00991","MPNGY","LU0608807433.USD","LU1814569148.SGD","LU1481107354.HKD","LU0049112450.USD","LU0164872284.USD","SG9999004311.SGD","BK1544","LU0738912210.USD","LU1439102457.SGD","IE00BGV7N243.SGD","LU0501845795.SGD","LU1152091168.USD","LU0049853897.USD","LU0348814723.USD","LU0577902298.EUR","LU0577902454.USD","LU0328353924.USD","80883","BK1614","LU0117841782.USD","80388","BK1550","LU1051768304.USD","LU0197773160.USD","BK1587","LU2279701549.SGD","01157","BK1610","SG9999001689.USD","LU0543330483.HKD","LU1770036033.HKD","LU0633140560.USD","LU0326948709.USD","LU2097828805.USD","LU1048484197.HKD","LU0052750758.USD","LU1497733557.USD","LU0633140727.USD","GB00BDT5M118.USD","LU1224444064.USD","LU1226288253.USD","BK1548","LU0163747925.USD","LU1734074674.USD","IE00B3T34201.USD","LU1808992512.USD","LU0229945570.USD","IE0001KFT4U8.USD","03033","LU1810669033.SGD","IE00B8HQ1Z84.USD","BK1152","LU0477156797.USD","SGXZ81514606.USD","LU0043850808.USD","BK1502","BK1506","LU0955623706.USD","LU0072913022.USD","BK1191","IE00B031HY20.USD","IE00B29SXG58.USD","LU1224709979.USD","LU0516422366.SGD","LU0345776255.USD","01347","LU0082770016.USD","LU0784639295.USD","BK1100","BK1586","LU0396098781.USD","LU0607220059.USD","LU0878004406.USD","LU1981816686.USD","LU0348784397.USD","LU2097829019.USD","BK1131","LU0449515922.USD","LU0011963245.USD","SG9999014914.USD","LU2097828631.EUR","LU0211331839.USD","02039","LU1102505929.USD","LU0348766576.USD","LU2317271919.USD","LU0348827113.USD","BK1507","LU0862451753.SGD","LU1960683339.HKD","LU1282648689.USD","LU0979878070.USD","SG9999014674.SGD","LU1794554557.SGD","LU0414403682.SGD","BK1604","LU0269904917.USD","LU2237443382.USD","LU0274383008.USD","LU0918141705.HKD","LU1831875114.USD","SG9999000327.SGD","SG9999006514.SGD","SG9999006597.SGD","BK1592","SGXZ90724238.SGD","LU0823397103.USD","LU1951186391.HKD","LU1051769294.HKD","LU0173614495.USD","LU1196710864.SGD","LU0865486749.SGD","LU0823413660.USD","HTCD.SI","IE00B0169N27.USD","LU2498475776.HKD","LU0348723411.USD","BK1608","LU2247934214.USD","LU2177674079.SGD","LU0140636845.USD","LU0516422440.USD","LU0096374516.USD","BK1233","01330","LU1969619763.USD","09988","LU1064130708.USD","SG9999001226.SGD","LU0509642566.USD","LU2133065610.SGD","LU1226287875.USD","LU0084288322.USD","LU1226287792.SGD","LU1323998911.USD","IE00BYV24P56.USD","LU0320764243.SGD","LU0531970944.HKD","01579","LU0823413587.USD","LU1655091459.SGD"],"gpt_icon":1},{"id":"1156466166","title":"HK Stock Movement | LUYE PHARMA (02186) Rises Over 3% as New Drug LY03017 Approved for Clinical Trials in the U.S. Targeting PDP and Other Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=1156466166","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156466166?lang=en_us&edition=fundamental","pubTime":"2025-11-26 10:22","pubTimestamp":1764123740,"startTime":"0","endTime":"0","summary":"LUYE PHARMA (02186) surged more than 3%, reaching HK$3.2 by the time of writing, with a trading volume of HK$28.32 million. On November 24, the company announced that its self-developed novel drug...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PDP","BK1606","BK1191","02186","BK1583"],"gpt_icon":0},{"id":"2585837455","title":"Luye Pharma Wins FDA IND Clearance for Next-Generation CNS Drug LY03017","url":"https://stock-news.laohu8.com/highlight/detail?id=2585837455","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585837455?lang=en_us&edition=fundamental","pubTime":"2025-11-24 14:20","pubTimestamp":1763965201,"startTime":"0","endTime":"0","summary":"Luye Pharma Group Ltd. has received clearance from the U.S. Food and Drug Administration  for its Investigational New Drug  application for LY03017, a next-generation serotonin 2A receptor  inverse agonist and serotonin 2C receptor  antagonist. This regulatory approval allows Luye Pharma to initiate clinical trials in the United States for LY03017, which is intended for the treatment of Alzheimer's disease psychosis, Parkinson's disease psychosis, and the negative symptoms of schizophrenia. The FDA has also exempted the single ascending dose trial in the Phase I study, permitting the company to proceed directly to multiple ascending dose and subsequent clinical trials.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Luye Pharma Group Lt","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL94y30f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","BK1583","BK1191","02186"],"gpt_icon":0},{"id":"2585213431","title":"Luye Pharma Gets U.S. FDA Nod to Start Trials for New CNS Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2585213431","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585213431?lang=en_us&edition=fundamental","pubTime":"2025-11-24 09:58","pubTimestamp":1763949503,"startTime":"0","endTime":"0","summary":"Luye Pharma  received U.S. FDA clearance to begin clinical trials for LY03017, its in-house developed dual-target central nervous system  drug, the company said in a Monday Hong Kong bourse filing.The agency also waived the single-ascending-dose requirement, allowing the program to move directly into multiple-ascending-dose testing.LY03017, intended for Alzheimer's disease psychosis, Parkinson's disease psychosis, and negative symptoms of schizophrenia, is already in a Phase 1 trial in China, the company said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","02186","CNS","BK4135","BK1583","BK1606"],"gpt_icon":0},{"id":"2585431176","title":"BRIEF-Luye Pharma Says Approval Obtained For LY03017 For Clinical Trials In U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2585431176","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585431176?lang=en_us&edition=fundamental","pubTime":"2025-11-24 09:53","pubTimestamp":1763949182,"startTime":"0","endTime":"0","summary":"BRIEF-Luye Pharma Says Approval Obtained For LY03017 For Clinical Trials In U.S.Nov 24 (Reuters) - Luye Pharma Group Ltd 2186.HK:APPROVAL OBTAINED FOR GROUP'S NEW DRUG LY03017 FOR CLINICAL TRIALS IN U.S.Further company coverage: 2186.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nFWN3WY00P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","BK1191","BK1583","02186"],"gpt_icon":0},{"id":"1126672924","title":"LUYE PHARMA (02186) Receives FDA Approval for Clinical Trials of New Drug LY03017 in the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=1126672924","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126672924?lang=en_us&edition=fundamental","pubTime":"2025-11-24 08:14","pubTimestamp":1763943276,"startTime":"0","endTime":"0","summary":"LUYE PHARMA (02186) announced that its self-developed novel drug LY03017, a next-generation 5-HT2A receptor inverse agonist and 5-HT2C receptor antagonist, has received approval from the U.S. Food...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1606","BK1583","02186"],"gpt_icon":0},{"id":"1162407018","title":"Luye Pharma (02186) Gains U.S. FDA Clearance for CNS Drug LY03017","url":"https://stock-news.laohu8.com/highlight/detail?id=1162407018","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162407018?lang=en_us&edition=fundamental","pubTime":"2025-11-24 08:04","pubTimestamp":1763942662,"startTime":"0","endTime":"0","summary":"Luye Pharma Group Ltd. (stock code: 02186) has obtained clearance from the U.S. Food and Drug Administration (FDA) to initiate clinical trials for LY03017, a next-generation serotonin 2A receptor...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186"],"gpt_icon":0},{"id":"2585435941","title":"Luye Pharma - Approval Obtained for Group's New Drug Ly03017 for Clinical Trials in U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2585435941","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585435941?lang=en_us&edition=fundamental","pubTime":"2025-11-24 08:00","pubTimestamp":1763942455,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nFWN3WY00P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1606","02186","BK1191","BK1583"],"gpt_icon":0},{"id":"2585167841","title":"Luye Pharma Unit to Raise $150 Million via Boan-Linked Exchangeable Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2585167841","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585167841?lang=en_us&edition=fundamental","pubTime":"2025-11-21 09:48","pubTimestamp":1763689702,"startTime":"0","endTime":"0","summary":"Luye Pharma Group (HKG:2186) said a wholly owned unit has agreed to issue $150 million in exchangeable preference shares to an independent subscriber, according to a Friday Hong Kong bourse filing.The","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06955","BK1606","BK1583","BK1191","02186","BK1161"],"gpt_icon":0},{"id":"1137707574","title":"Luye Pharma Group (02186) Announces US$150 Million Exchangeable Preference Shares Linked to Boan Biotech (06955)","url":"https://stock-news.laohu8.com/highlight/detail?id=1137707574","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137707574?lang=en_us&edition=fundamental","pubTime":"2025-11-21 07:22","pubTimestamp":1763680948,"startTime":"0","endTime":"0","summary":"Luye Pharma Group Ltd (02186) announced that on 21 November 2025, its wholly-owned subsidiary, Luye Geneora Holding Limited (the Issuer), together with Luye Pharma Group as guarantor and an...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186"],"gpt_icon":0},{"id":"2585165298","title":"Luye Pharma Subsidiary Issues Exchangeable Preference Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2585165298","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585165298?lang=en_us&edition=fundamental","pubTime":"2025-11-21 07:17","pubTimestamp":1763680626,"startTime":"0","endTime":"0","summary":"Luye Pharma Group Ltd. announced that its wholly-owned subsidiary, Luye Geneora Holding Limited, has issued exchangeable preference shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Luye Pharma Group Ltd. published the original content used to generate this news brief on November 21, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL3cV6cz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1191","BK1606","02186"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.luye.cn","stockEarnings":[{"period":"1week","weight":-0.0204},{"period":"1month","weight":-0.0619},{"period":"3month","weight":-0.1818},{"period":"6month","weight":-0.1325},{"period":"1year","weight":0.3333},{"period":"ytd","weight":0.3272}],"compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0054},{"period":"3month","weight":-0.0322},{"period":"6month","weight":0.0918},{"period":"1year","weight":0.3006},{"period":"ytd","weight":0.2807}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Luye Pharma Group Ltd is a company mainly engaged in developing, producing, marketing and selling pharmaceutical products. The Company operates four segments, including Oncology Drugs segment, Cardiovascular System Drugs segment, Alimentary Tract and Metabolism Drugs segment, and Central Nervous System Drugs segment. The Oncology Drugs segment provides Lipusu, Boyounuo, Baituowei, CMNa and Mimeixin and other drugs. The Cardiovascular System Drugs segment provides Xuezhikang, Oukai and Maitongna and other drugs. The Alimentary Tract and Metabolism Drugs segment provides Bei Xi and other drugs. The Central Nervous System Drugs segment provides Seroquel, Ruoxinlin, Rykindo, Meibirui and Jinyouping and other drugs.","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.02774},{"month":2,"riseRate":0.363636,"avgChangeRate":0.023841},{"month":3,"riseRate":0.363636,"avgChangeRate":-0.021667},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.009215},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.0086},{"month":6,"riseRate":0.363636,"avgChangeRate":0.035296},{"month":7,"riseRate":0.636364,"avgChangeRate":0.018026},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.044846},{"month":9,"riseRate":0.583333,"avgChangeRate":0.045957},{"month":10,"riseRate":0.5,"avgChangeRate":-0.00637},{"month":11,"riseRate":0.5,"avgChangeRate":0.024651},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.008897}],"exchange":"SEHK","name":"LUYE PHARMA","nameEN":"LUYE PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LUYE PHARMA(02186),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest LUYE PHARMA(02186) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"LUYE PHARMA,02186,LUYE PHARMA股票,LUYE PHARMA股票老虎,LUYE PHARMA股票老虎国际,LUYE PHARMA行情,LUYE PHARMA股票行情,LUYE PHARMA股价,LUYE PHARMA股市,LUYE PHARMA股票价格,LUYE PHARMA股票交易,LUYE PHARMA股票购买,LUYE PHARMA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LUYE PHARMA(02186),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest LUYE PHARMA(02186) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}